Raffaele Giusti

CTO Andrea Alesini — Italy

Medicine · Health Sciences

36h-index6.3kcitations341works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(162), Diabetes Treatment and Management(82), Pancreatic and Hepatic Oncology Research(64), Lung Cancer Treatments and Mutations(49), Neutropenia and Cancer Infections(31)

Publications339 total

“I’m thrilled to share”: ego, social media, and the quiet distortion of scientific communication
Recenti Progressi in Medicina·2025Open Access
Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Alessio Cortellini(30), Marco Filetti(26), Paolo Marchetti(23), Federica Zoratto(19), Rita Chiari(19), Corrado Ficorella(19), Rossana Berardi(18), Michele De Tursi(16), Andrea Botticelli(16), Alain Gelibter(16), Giampiero Porzio(16), Sebastiano Buti(15), Francesco Grossi(14), Marcello Tiseo(14), Melissa Bersanelli(14), Daniele Santini(14), Marco Russano(14), Francesca Mazzoni(14), Olga Nigro(13), Pietro Di Marino(12)